Crossject | ALCJ FP | Supergenerics | France | Updates

This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject ^CR	Bloomberg ALCJ FP
Supergenerics / France	Web Site \| Investors Relation

Things get going

Target

Upside 435%

Price (€) 2.13

Target Price (€) 11.4

Market Cap (€M) 77.8

Perf. 1W:	2.65%
Perf. 1M:	-36.2%
Perf. 3M:	-59.2%
Perf Ytd:	-57.1%

10 day relative perf. to stoxx600:	-1.42%
20 day relative perf. to stoxx600:	-35.4%

EPS change22/05/2020

Download

No major changes after the release of the FY19 report
Change in EPS	2019 : € -0.49 vs -0.48	ns
	2020 : € -0.32 vs -0.34	ns
No major changes to our forecasts. The only ones come from the integration of the detailed FY19 numbers which marginally impact our forecasts, with hardly any change to our target price.

18 Jun 21 Latest
Another good piece of news for the group

17 Jun 21 Latest
A licensing agreement for Zeneo Hydrocortison...

31 Mar 21 Earnings/sales releases
FY20 unsuprising; waiting for more

15 Dec 20 Financing issue
A double bond issue

21 Sep 20 Earnings/sales releases
Update on the group's business

22 May 20 EPS change
No major changes after the release of the FY19...

29 Mar 20 Earnings/sales releases
Meaningless FY19 results and product update

23 Dec 19 Financing issue
Extra-financing to increase visibility

20 Nov 19 Financing issue
A €2.6m non-dilutive issue

15 Oct 19 Latest
Cooperation agreement with the US Departmen...